apceth and Indivumed to Develop Biomarker Platform for Targeted Cellular Therapies
apceth GmbH & Co. KG and Indivumed GmbH have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics. The goal is to predict the response of a targeted cellular / gene therapy in different cancer types and to stratify patients to provide a more individualized cancer treatment with apceth’s cell and cell-based gene therapeutics. A reliable biomarker platform will enable oncologists to identify those patients who will most likely benefit from the treatment with apceth’s therapeutics, thus establishing a unique and truly personalized therapeutic approach adapted to the needs of each cancer patient.
Since biomarkers for cell and gene therapeutics are not yet available and cancer is still a growing medical problem worldwide, significant demand for an adequate and reliable biomarker platform exists.
A special analytical platform for cancer tissue allows Indivumed to identify and validate protein biomarkers and targets with extremely high reliability in terms of their clinical application. One of Indivumed’s strengths is analyzing cancer pathway molecules for predicting drug response. apceth wants to make use of Indivumed’s highly regarded tumor tissue bank and its expertise in tissue-based biomarker discovery and validation. Both companies believe that the combination of apceth’s therapeutic approach and Indivumed’s biomarker platform has the potential to drive future cancer therapeutics and pharmaceutical innovation, thereby making the promises for personalized medicine a reality.
apceth Biopharma GmbH announces that Hitachi Chemical Co., Ltd. will enter into an agreement to acquire all shares of apceth Biopharma GmbH. This acquisition is expected to close in April 2019.
Founded 2007, apceth is a pioneer in cell and gene therapy and has developed into a leading Europ ... more
apceth GmbH & Co. KG is continuing to expand its senior management team and has announced the appointment of Ulrike Verzetnitsch as Chief Technical Officer with immediate effect.In this newly created role, Ulrike Verzetnitsch will add considerable value to the company by leading apceth’s pr ... more
apceth announced the successful completion of the Phase I and initiation of the Phase II part of its ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, at the Klinikum Grosshadern in Munich. To the company’s knowledge, thi ... more
Evotec SE and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer.
Under the terms of the collaboration agreement, Evotec received full access to the colorect ... more
Evotec SE and Indivumed GmbH announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary b ... more
Indivumed announced that Helge Bastian, Ph.D, will join Indivumed as Managing Director and Chief Commercial Officer on September 12, 2011.
Dr. Bastian has over 19 years of international leadership experience in corporations serving the molecular biology, life science research, diagnostics, ... more
Indivumed GmbH generates, characterizes and analyzes highly standardized biological samples from human cancer patients under ISO-9001:2008 standards. The company inte-grates a unique infrastructure of proprietary clinical and laboratory facilities with an outstand-ing biospecimen biobank of ... more